Evidence map›Paper›PMID 37707761›Full record

ReviewInternational journal of hematology2023

Myeloid sarcoma and pathological fracture: a case report and review of literature.

Sho Takeyasu, Ken Morita, Seitaro Saito, Masanori Toho, Takashi Oyama, Takafumi Obo, Kazuki Taoka, Arika Shimura, Hiroaki Maki, Eisuke Shibata and 6 more

Open access · hybridAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Sho TakeyasuDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Ken MoritaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Seitaro SaitoDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Masanori TohoDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Takashi OyamaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Takafumi OboDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Kazuki TaokaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Arika ShimuraDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Hiroaki MakiDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Eisuke ShibataDepartment of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yusuke WatanabeDepartment of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Fumio SuzukiDepartment of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Liuzhe ZhangDepartment of Orthopedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroshi KobayashiDepartment of Orthopedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Munetoshi HinataDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. kurokawa@m.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-4034-2422
The University of Tokyo · JP

Funding

Japan Society for the Promotion of Science 21H04805
6 · The paper itself

Abstract

Myeloid sarcoma is a rare clinical entity that presents as an isolated proliferation of leukemic cells, concurrently with or at relapse of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), chronic myeloid leukemia (CML), and myeloproliferative neoplasm (MPN). Myeloid sarcoma disrupts the normal architecture of its surrounding tissues. When it forms in long bones, it can cause their pathological fracture. We recently experienced a rare case of MDS presenting with myeloid sarcoma in the femur that eventually resulted in its pathological fracture. Detailed chromosomal analysis of the bone marrow cells suggested emergence of myeloid sarcoma during the fast-paced progression of MDS just after acquiring trisomy 22. A comprehensive review of previous cases of myeloid sarcoma-associated pathological fracture indicated possible involvement of structural rearrangements of chromosomes 9 and 22. Management of myeloid sarcoma should continue to improve, and clinicians should note that myeloid sarcoma with specific chromosomal alterations needs extra medical attention to prevent pathological fracture.

Indexed as

Fractures, SpontaneousLeukemia, Myeloid, AcuteMyelodysplastic SyndromesMyeloproliferative DisordersSarcoma, MyeloidHumansMyelodysplastic syndromes/neoplasmsMyeloid sarcomaPathological fracture

Identifiers

PMID37707761
PMCPMC10673718
OpenAlexW4386726078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.